Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0HI5D
|
|||
| Drug Name |
Naxitamab
|
|||
| Indication | Neuroblastoma [ICD-11: 2D11.2; ICD-9: 194] | Approved | [1] | |
| Osteosarcoma [ICD-11: 2B51; ICD-9: 170] | Phase 2 | [2] | ||
| Company |
Y-mAbs Therapeutics New York, NY
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.